NO991225L - Terapi for <alfa>-galaktosidase A mangel - Google Patents

Terapi for <alfa>-galaktosidase A mangel

Info

Publication number
NO991225L
NO991225L NO991225A NO991225A NO991225L NO 991225 L NO991225 L NO 991225L NO 991225 A NO991225 A NO 991225A NO 991225 A NO991225 A NO 991225A NO 991225 L NO991225 L NO 991225L
Authority
NO
Norway
Prior art keywords
galactosidase
alfa
therapy
deficiency
sample
Prior art date
Application number
NO991225A
Other languages
English (en)
Other versions
NO328443B1 (no
NO991225D0 (no
Inventor
Richard F Selden
Marianne Borowski
Francis P Gillespie
Carol M Kinoshita
Douglas A Treco
Melanie D Williams
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of NO991225D0 publication Critical patent/NO991225D0/no
Publication of NO991225L publication Critical patent/NO991225L/no
Publication of NO328443B1 publication Critical patent/NO328443B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO19991225A 1996-09-13 1999-03-12 DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert. NO328443B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13
PCT/US1997/016603 WO1998011206A2 (en) 1996-09-13 1997-09-12 THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (3)

Publication Number Publication Date
NO991225D0 NO991225D0 (no) 1999-03-12
NO991225L true NO991225L (no) 1999-05-10
NO328443B1 NO328443B1 (no) 2010-02-22

Family

ID=24862863

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19991225A NO328443B1 (no) 1996-09-13 1999-03-12 DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.
NO20090583A NO330687B1 (no) 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no) 1996-09-13 2011-03-31 Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no) 1996-09-13 2014-09-29 Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20090583A NO330687B1 (no) 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no) 1996-09-13 2011-03-31 Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no) 1996-09-13 2014-09-29 Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Country Status (21)

Country Link
EP (4) EP1538202B1 (no)
JP (7) JP4001925B2 (no)
KR (2) KR100547402B1 (no)
CN (1) CN1268741C (no)
AT (1) ATE286120T1 (no)
AU (1) AU4424497A (no)
CA (1) CA2265464C (no)
DE (1) DE69732129T2 (no)
DK (2) DK1538202T3 (no)
ES (3) ES2458292T3 (no)
HK (3) HK1022173A1 (no)
HU (2) HU230275B1 (no)
IL (2) IL128960A (no)
MX (1) MX340738B (no)
NO (4) NO328443B1 (no)
NZ (2) NZ334721A (no)
PL (1) PL190041B1 (no)
PT (1) PT1538202E (no)
RU (1) RU2179034C2 (no)
TW (1) TW585919B (no)
WO (1) WO1998011206A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
WO2000009153A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
CA2398995C (en) 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US7935336B2 (en) 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
WO2008143354A1 (ja) * 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
CA2796607C (en) 2010-04-23 2019-09-10 Synageva Biopharma Corp Lysosomal storage disease enzyme
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
AU2011314293B2 (en) 2010-09-09 2015-06-04 Alexion Pharmaceuticals, Inc. Use of Lysosomal Acid Lipase for treating Lysosomal Acid Lipase Deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
SI2773438T2 (sl) * 2011-11-02 2022-05-31 F.Hoffmann-La Roche Ag Izpiralna kromatografija s preobremenitvijo
US9623090B2 (en) 2012-03-02 2017-04-18 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type III gaucher disease
BR112014032919B1 (pt) * 2012-06-29 2023-03-28 Universitat De Barcelona Conjugado e seu método de produção, lipossomas, uso e método de produção dos mesmos, bem como composição farmacêutica
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014066471A1 (en) 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
EP4234699A1 (en) 2014-12-22 2023-08-30 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN116270739A (zh) 2017-06-30 2023-06-23 富士胶片株式会社 细胞结构体在制造溶酶体贮积病处置剂中的用途
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
AU2019403323A1 (en) 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
DE3887425T2 (de) * 1987-10-02 1994-06-23 Zymogenetics Inc BAR1-Sekretions-Signal-Sequenz.
WO1990011353A1 (en) * 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
CA2022983A1 (en) * 1989-08-11 1991-02-12 Mei-Huei Lai Expression of a functional insect specific toxin gene in mammalian cells
CA2092823A1 (en) * 1990-09-28 1992-03-29 Barry D. Greenberg Transgenic animals with alzheimer's amyloid precursor gene
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2098599A1 (en) * 1991-10-16 1993-04-17 William F. Swain Particle-mediated transformation of animal somatic cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0726944B1 (en) * 1993-07-02 2002-12-18 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
ES2260568T3 (es) 1994-01-13 2006-11-01 The Rogosin Institute Celulas secretoras macroencapsuladas.
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
ATE323724T1 (de) * 1995-02-15 2006-05-15 Amgen Inc Mpl-liganden analoga

Also Published As

Publication number Publication date
PL332188A1 (en) 1999-08-30
DE69732129D1 (de) 2005-02-03
AU4424497A (en) 1998-04-02
IL184637A (en) 2015-07-30
JP2007289201A (ja) 2007-11-08
NO328443B1 (no) 2010-02-22
KR20050084473A (ko) 2005-08-26
JP2012019793A (ja) 2012-02-02
JP4313381B2 (ja) 2009-08-12
JP5590788B2 (ja) 2014-09-17
ES2234032T3 (es) 2005-06-16
HU227189B1 (en) 2010-10-28
CA2265464C (en) 2007-06-26
WO1998011206A2 (en) 1998-03-19
EP2327775A2 (en) 2011-06-01
JP2009102321A (ja) 2009-05-14
DK1538202T3 (en) 2014-03-24
JP2001504324A (ja) 2001-04-03
NO991225D0 (no) 1999-03-12
ES2458292T3 (es) 2014-04-30
HK1022173A1 (en) 2000-07-28
NZ506214A (en) 2002-11-26
JP4313405B2 (ja) 2009-08-12
JP2007000145A (ja) 2007-01-11
EP1538202A2 (en) 2005-06-08
KR20000036078A (ko) 2000-06-26
JP2009060918A (ja) 2009-03-26
DK2374876T3 (en) 2016-05-30
HU1000445D0 (en) 2010-11-29
NO20110496L (no) 1999-05-10
WO1998011206A3 (en) 1998-08-13
MX340738B (es) 2016-07-22
HK1074058A1 (en) 2005-10-28
CN1268741C (zh) 2006-08-09
TW585919B (en) 2004-05-01
NO330687B1 (no) 2011-06-06
EP2327775A3 (en) 2012-10-24
EP0935651A2 (en) 1999-08-18
EP2374876A3 (en) 2012-10-24
NO20090583L (no) 1999-05-10
PT1538202E (pt) 2014-04-22
EP1538202A3 (en) 2007-05-30
NO20141168L (no) 1999-05-10
JP4001925B2 (ja) 2007-10-31
ES2581828T3 (es) 2016-09-07
RU2179034C2 (ru) 2002-02-10
CN1230220A (zh) 1999-09-29
PL190041B1 (pl) 2005-10-31
IL184637A0 (en) 2009-09-22
CA2265464A1 (en) 1998-03-19
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
EP2374876B1 (en) 2016-04-13
NO340408B1 (no) 2017-04-18
NZ334721A (en) 2001-01-26
HK1162580A1 (zh) 2012-08-31
KR100547402B1 (ko) 2006-02-01
JP2015044830A (ja) 2015-03-12
DE69732129T2 (de) 2005-12-08
HU9904666A (en) 2000-05-28
HU230275B1 (hu) 2015-11-30
IL128960A (en) 2007-10-31
EP2374876A2 (en) 2011-10-12
ATE286120T1 (de) 2005-01-15
EP1538202B1 (en) 2014-01-22
EP0935651B1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
NO991225L (no) Terapi for &lt;alfa&gt;-galaktosidase A mangel
FI20050238A (fi) Markfortiini- ja paraherkvamidiyhdisteet
ITRM940150A0 (it) Procedimento per il trattamento di acque di scarico fortemente colorate.
AU5534996A (en) Antibody purification by low-pH hydrophobic interaction chromatography
EP0381184A3 (en) Catalysts for the polymerization of olefins
DE19781288T1 (de) Opake Reaktionsmatrix zur Analyse von Vollblut
DK0832097T3 (da) System og fremgangsmåde til modifikation og rensning af peptider
LTIP1891A (en) Method for the purification of taxoides
DE69612991D1 (de) System zur bearbeitung von selbstmodifizierendem kode
PT1027339E (pt) Metodo e reagentes para a n-alquilacao de ureidos
DK0785949T3 (da) Fremgangsmåde til oprensning af keratinocytvækstfaktorer
EP0603671A3 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen.
FR2674248B1 (fr) Procede de modification chimique des proteines.
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
AU6670690A (en) Benzothiazepines
WO1997005253A3 (de) Transketolase-verwandtes protein
FR2702777B1 (fr) Procede de nickelage chimique.
ITTO930166A0 (it) Procedimento per il trattamento di flussi reflui della produzione di n-fosfonometilglicina.
HUT67823A (en) Process for the production of leather treating substance from environment-damaging, protein sewage
DE59402942D1 (de) Vergleichsverfahren für steuerprogramm-quellcode
RU2069492C1 (ru) Штамм бактерий rhodococcus species 1418 (r.ruber), используемый для очистки почв и водоемов от нефти и нефтепродуктов
FI963244A (fi) Menetelmä 2-butyyli-2-etyyli-1,3-propaanidiolin erottamiseksi sitä sisältävistä reaktioseoksista
DK0813518T3 (da) Fremgangsmåde til fremstilling af alfa,beta-diaminoacrylnitriler
PL308056A1 (en) Compound reactor for biological sewage treatment

Legal Events

Date Code Title Description
MK1K Patent expired